Bitosen Bilastine 20mg 30 tabs

$40.00

Second generation antihistamine, treatment of allergic rhinoconjunctivitis and urticaria.

Free international shipping

Description

Pharmacological group:

Antihistamines for systemic use. Other antihistamines for systemic use. Bilastine. ATX code R06A X29.

Composition:

Active ingredient:

bilastine; 1 tablet contains 20 mg bilastine Nixar excipients: microcrystalline cellulose, sodium starch (type A), colloidal silicon dioxide, magnesium stearate.

Indications:

Symptomatic treatment of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria.

Contraindications:

Hypersensitivity to the active substance or to any of the excipients.

Method of administration and dosage:

Adults and children:

(over 12 years old). 20 mg bilastine (1 tablet) once a day to relieve symptoms of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria.
The tablet should be taken 1 hour before or 2 hours after a meal or fruit juice
.

Special patient groups:

Elderly patients: Elderly patients do not need dose adjustment

In case of impaired renal function: No dose adjustment is required for patients with impaired renal function

In case of impaired liver function:

There is no experience of clinical use of the drug in patients with impaired liver function. Since bilastine is not amenable to metabolism and is excreted by the kidneys, impaired liver function should not lead to an increase in its systemic action to a dangerous level. Therefore, dose adjustment is not required for patients with impaired liver function.

Children:

The use of bilastine for allergic rhinoconjunctivitis and urticaria in children aged 0 to 2 years is inappropriate. The safety and efficacy of use in children under 12 years of age have not yet been established.

Duration of treatment:

For patients with allergic rhinitis, the drug should be used only during contact with allergens. In patients with seasonal allergic rhinitis, treatment can be discontinued after symptoms have subsided and resumed when symptoms return. For patients with perennial allergic rhinitis, the drug can be used continuously during the period of contact with allergens. In patients with urticaria, the duration of treatment depends on the nature and duration of the symptoms, as well as on their dynamics.

Mode of application:

For oral administration.
The tablets should be taken with water. It is recommended to take the daily dose at one time.

The ability to influence the reaction rate when driving or operating machinery:
A study of the effect of the drug on the ability to drive vehicles demonstrated that in adults, treatment with  a dose of 20 mg did not affect the ability to drive vehicles. However, patients should be informed that in some cases, the drug may cause drowsiness and, thus, affect the ability to drive vehicles or operate machinery.
Application during pregnancy or lactation:
Pregnancy: Data on the use of the drug in pregnant women are lacking or limited. Animal studies have not shown any direct or indirect adverse effects on reproductive function, childbirth or postnatal development. For safety reasons, it is advisable to avoid taking Nixar during pregnancy.
Lactation: Research on the excretion of the drug in breast milk has not been conducted. Available pharmacokinetic data have shown that it passes into breast milk in animals. The decision to continue / discontinue breastfeeding or to discontinue / abstain from Nixar therapy should be made taking into account the benefits of breastfeeding for the baby and the benefits of the therapy for the mother.
Fertility: Clinical data are limited or not available. Studies in rats have shown no negative effects on fertility.
Shelf life:

5 years.
Storage conditions:
Store in its original packaging at a temperature not exceeding 25 °C.

Produced in Germany